Q2 Earnings Estimate for Personalis Issued By HC Wainwright

Personalis, Inc. (NASDAQ:PSNL - Free Report) - Investment analysts at HC Wainwright reduced their Q2 2025 earnings estimates for Personalis in a note issued to investors on Wednesday, May 7th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of ($0.26) per share for the quarter, down from their prior forecast of ($0.23). HC Wainwright has a "Buy" rating and a $9.00 price objective on the stock. The consensus estimate for Personalis' current full-year earnings is ($1.40) per share. HC Wainwright also issued estimates for Personalis' Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.00) EPS, Q1 2026 earnings at ($0.27) EPS, Q2 2026 earnings at ($0.26) EPS, Q3 2026 earnings at ($0.25) EPS, Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($1.03) EPS, FY2027 earnings at ($0.62) EPS, FY2028 earnings at ($0.35) EPS and FY2029 earnings at $0.02 EPS.

Several other equities research analysts have also recently weighed in on the stock. Needham & Company LLC restated a "buy" rating and issued a $7.00 price objective on shares of Personalis in a research report on Thursday, April 10th. Craig Hallum initiated coverage on shares of Personalis in a research report on Monday, March 17th. They issued a "buy" rating and a $8.00 price objective for the company. Finally, Guggenheim began coverage on Personalis in a report on Thursday. They set a "buy" rating and a $6.00 price objective on the stock. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $7.67.

Personalis Trading Up 1.3%

Shares of Personalis stock traded up $0.06 during trading on Monday, reaching $4.95. The company's stock had a trading volume of 88,953 shares, compared to its average volume of 1,001,823. The stock has a 50-day moving average price of $3.74 and a two-hundred day moving average price of $4.47. The stock has a market capitalization of $437.39 million, a P/E ratio of -2.96 and a beta of 1.83. Personalis has a one year low of $1.14 and a one year high of $7.20.

Personalis (NASDAQ:PSNL - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.05. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. The business had revenue of $20.61 million for the quarter, compared to analyst estimates of $17.41 million.

Hedge Funds Weigh In On Personalis

A number of hedge funds and other institutional investors have recently bought and sold shares of PSNL. Royal Bank of Canada lifted its stake in shares of Personalis by 3.2% in the 1st quarter. Royal Bank of Canada now owns 78,341 shares of the company's stock valued at $275,000 after purchasing an additional 2,395 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in Personalis by 18.2% in the first quarter. China Universal Asset Management Co. Ltd. now owns 17,704 shares of the company's stock valued at $62,000 after buying an additional 2,724 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new position in Personalis during the fourth quarter worth about $28,000. Stifel Financial Corp grew its position in shares of Personalis by 25.0% during the 4th quarter. Stifel Financial Corp now owns 25,000 shares of the company's stock worth $144,000 after buying an additional 5,000 shares during the period. Finally, JPMorgan Chase & Co. increased its stake in shares of Personalis by 2,827.0% in the 4th quarter. JPMorgan Chase & Co. now owns 5,854 shares of the company's stock valued at $34,000 after acquiring an additional 5,654 shares during the last quarter. 61.91% of the stock is owned by institutional investors.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.